<DOC>
	<DOCNO>NCT00311363</DOCNO>
	<brief_summary>The primary objective trial ass maintenance efficacy gabapentin enacarbil ( GEn , XP13512 ) take daily long-term treatment patient suffer Restless Legs Syndrome ( RLS ) .</brief_summary>
	<brief_title>Long-Term Study Gabapentin Enacarbil ( GEn , XP13512 ) v . Placebo Patients With Restless Legs Syndrome .</brief_title>
	<detailed_description>This study multicenter , blind , randomize withdrawal study subject primary Restless Legs Syndrome ( RLS ) . Eligible subject initially enrol 24-week single blind ( SB ) treatment period receive XP13512 . Subjects complete initial treatment period meet responder criterion randomize 1:1 receive either XP13512 placebo 12-week double-blind ( DB ) treatment period . The primary study objective ass maintenance efficacy XP13512 1200 mg take daily long-term treatment subject primary RLS . The secondary study objective assess maintenance improvement sleep outcome quality life , assess safety tolerability XP13512 treatment primary RLS subject .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients primary RLS , base International RLS Study Group Diagnostic Criteria . A sleep disorder ( e.g. , sleep apnea ) may significantly affect assessment RLS ; Neurologic disease movement disorder ( e.g. , diabetic neuropathy , Parkinson 's disease , Multiple Sclerosis , dyskinesia , dystonias ) ; Abnormal laboratory result , electrocardiogram ( ECG ) physical finding ; Pregnant lactate woman ; Women childbearing potential practicing acceptable method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>